Atea Pharmaceuticals (AVIR) to Release Earnings on Monday

Atea Pharmaceuticals (NASDAQ:AVIR) is expected to be issuing its Q1 2025 quarterly earnings results after the market closes on Monday, May 12th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.

Atea Pharmaceuticals (NASDAQ:AVIR) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). On average, analysts expect Atea Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Atea Pharmaceuticals Price Performance

Shares of AVIR opened at $2.72 on Friday. The company has a market capitalization of $232.77 million, a price-to-earnings ratio of -1.31 and a beta of 0.17. Atea Pharmaceuticals has a 1 year low of $2.60 and a 1 year high of $4.15. The business has a 50-day moving average of $2.93 and a 200-day moving average of $3.12.

Analyst Ratings Changes

A number of brokerages have commented on AVIR. Morgan Stanley decreased their price target on shares of Atea Pharmaceuticals from $6.20 to $6.00 and set an “equal weight” rating for the company in a research note on Friday, April 11th. William Blair reissued an “outperform” rating on shares of Atea Pharmaceuticals in a report on Friday, March 7th.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.